S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:URGN

UroGen Pharma (URGN) Stock Price, News & Analysis

$14.96
-0.21 (-1.38%)
(As of 03/27/2024 ET)
Today's Range
$14.46
$15.67
50-Day Range
$14.27
$19.33
52-Week Range
$7.79
$24.13
Volume
248,981 shs
Average Volume
348,645 shs
Market Capitalization
$350.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.67

UroGen Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
211.9% Upside
$46.67 Price Target
Short Interest
Bearish
18.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.45mentions of UroGen Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$306,829 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.59) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.04 out of 5 stars

Medical Sector

204th out of 939 stocks

Pharmaceutical Preparations Industry

84th out of 422 stocks

URGN stock logo

About UroGen Pharma Stock (NASDAQ:URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock Price History

URGN Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer
UroGen: All Eyes On UGN-102
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
UroGen Pharma earnings preview: what to expect
3 Biotech Stocks Climbing the Ranks to Watch
URGN Mar 2024 22.500 call
URGN Mar 2024 17.500 call
URGN Mar 2024 10.000 put
UroGen Pharma Ltd URGN
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.67
High Stock Price Target
$54.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+211.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-102,240,000.00
Net Margins
-123.61%
Pretax Margin
-118.87%

Debt

Sales & Book Value

Annual Sales
$82.71 million
Book Value
($2.78) per share

Miscellaneous

Free Float
20,844,000
Market Cap
$350.81 million
Optionable
Optionable
Beta
1.09
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


URGN Stock Analysis - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price target for 2024?

2 brokers have issued twelve-month price targets for UroGen Pharma's shares. Their URGN share price targets range from $34.00 to $54.00. On average, they expect the company's share price to reach $46.67 in the next twelve months. This suggests a possible upside of 211.9% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2024?

UroGen Pharma's stock was trading at $15.00 at the beginning of the year. Since then, URGN shares have decreased by 0.3% and is now trading at $14.96.
View the best growth stocks for 2024 here
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.05. The firm earned $23.53 million during the quarter, compared to analyst estimates of $22.30 million.

What ETF holds UroGen Pharma's stock?

ARK Israel Innovative Technology ETF holds 218,434 shares of URGN stock, representing 1.96% of its portfolio.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (7.36%), Superstring Capital Management LP (1.09%), Northern Trust Corp (1.00%), Parkman Healthcare Partners LLC (0.75%), Vanguard Group Inc. (0.73%) and Vanguard Group Inc. (0.73%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg and Molly Henderson.
View institutional ownership trends
.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:URGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners